Lamivudine and Dolutegravir

ViiV Healthcare's DOLCE study showed Dovato, a two-drug regimen, had similar efficacy to a three-drug therapy in viral suppression for advanced HIV patients, with 82% achieving viral suppression at 48 weeks, compared to 80% in the three-drug arm. Safety profiles were also comparable.

DOLCE study shows Dovato (DTG/3TC) is effective and safe for treatment-naive adults with advanced HIV, comparable to a 3-drug regimen, even in those with low CD4 counts and high viral loads.

ViiV Healthcare plans to triple its HIV prevention therapy supply at not-for-profit prices in low- and middle-income countries by 2026, committing to 2 million doses of long-acting cabotegravir for pre-exposure prophylaxis. This move aims to accelerate HIV prevention in resource-limited, high-burden countries.